<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>Clinical Summary – Carbamazepine Intolerance and Drug Sensitivity Pattern</title>
  <meta name="description" content="Concise clinical summary of carbamazepine intolerance, autonomic reaction, and historical sensitivity to neuro-active drugs, with ambulance assessment and ECG values." />

  <!-- Open Graph / Twitter -->
  <meta property="og:title" content="Clinical Summary – Carbamazepine Intolerance" />
  <meta property="og:description" content="Autonomic and mast-cell type reactions to carbamazepine, mirroring prior responses to duloxetine, gabapentin, pregabalin, amitriptyline. Includes ambulance visit and normal ECG." />
  <meta property="og:type" content="website" />
  <meta property="twitter:card" content="summary_large_image" />

  <link href="https://cdn.jsdelivr.net/npm/bootstrap@5.3.3/dist/css/bootstrap.min.css" rel="stylesheet" />
  <link rel="preconnect" href="https://fonts.googleapis.com">
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  <link href="https://fonts.googleapis.com/css2?family=Montserrat:ital,wght@0,100..900;1,100..900&display=swap" rel="stylesheet">
 <link href="../global_styles.css" rel="stylesheet" />
</head>
<body>
  <main class="content container">
    <nav aria-label="breadcrumb">
      <ol class="breadcrumb">
        <li class="breadcrumb-item"><a href="/medical">Medical</a></li>
        <li class="breadcrumb-item"><a href="/medical/neurological">Neurological</a></li>
        <li class="breadcrumb-item active" aria-current="page">Clinical Summary</li>
      </ol>
    </nav>

    <header>
      <h1>Clinical Summary – Carbamazepine Intolerance</h1>
      <p class="meta">Prepared: 12 Oct 2025</p>
    </header>

    <section class="section card-like">
      <h2>Context</h2>
      <p>History of intolerance to duloxetine, gabapentin, pregabalin, and amitriptyline with autonomic and histaminic features. Carbamazepine 100 mg was trialled as a reluctant final conventional option under neurology guidance.</p>
    </section>

<section class="section card-like" id="recent-events">
  <h2>Recent Events</h2>
  <div class="table-wrap">
    <table>
      <tbody>
        <tr>
          <th>11 Oct 2025</th>
          <td>
            Autonomic episode after a warm bath at ~13:00, approximately 22 hours after 100 mg carbamazepine (15:00 on 10 Oct). Dizziness, near-syncope, pulse variability 111 → 85 → 110 bpm, chest and left arm tightness, facial tingling, occipital constriction, headache. Sat on the floor until stable. Considered calling 111/ambulance. <a href="Autonomic_Episode_After_Bath_2025-10-11.html">Full entry</a>.
          </td>
        </tr>
        <tr>
          <th>12 Oct 2025</th>
          <td>
            Generalised pruritus several hours after second 100 mg dose: scalp, underarms, chest, groin; heat–cold mismatch; sleep disrupted; no visible rash at time of logging. <a href="Medication_Log_Carbamazepine_2025-10-12.html">Full entry</a>.
          </td>
        </tr>
        <tr>
          <th>12 Oct 2025</th>
          <td>
            111 called. Ambulance attendance after ~2.5 hours. Took chlorphenamine 4mg, cooled outside, nicotine used, symptoms improved prior to arrival. Paramedics recorded stable vitals and normal ECG; discharged with advice to follow up GP/neurology.
          </td>
        </tr>
      </tbody>
    </table>
  </div>
</section>

    <section class="section card-like">
      <h2>ECG Parameters (Paramedic Printout)</h2>
      <table>
        <tr><th>Heart rate</th><td>100 bpm</td></tr>
        <tr><th>PR interval</th><td>126 ms</td></tr>
        <tr><th>QRS duration</th><td>91 ms</td></tr>
        <tr><th>QT interval</th><td>328 ms</td></tr>
        <tr><th>QTc</th><td>425 ms</td></tr>
        <tr><th>P axis</th><td>80°</td></tr>
        <tr><th>QRS axis</th><td>73°</td></tr>
        <tr><th>T axis</th><td>95°</td></tr>
      </table>
      <p class="meta">Interpretation: within normal limits for rate-adjusted intervals and axes. No acute electrical abnormality identified.</p>
    </section>

    <section class="section card-like">
      <h2>Clinical Interpretation</h2>
      <p>Pattern is consistent with autonomic and mast-cell activation in response to neuro-active agents, now including carbamazepine. This mirrors prior reactions to duloxetine and tricyclics where antihistamines were advised with only marginal help. The reactions are physiological and reproducible across classes.</p>
    </section>

    <section class="section card-like">
      <h2>Requests to Care Team</h2>
      <ul>
        <li>Record carbamazepine as <strong>intolerant / adverse reaction</strong>.</li>
        <li>Consider <strong>mast-cell workup</strong> (baseline and event tryptase, plasma/urine histamine, DAO).</li>
        <li>Consider <strong>pharmacogenomic profiling</strong> for CYP2D6/CYP3A4 and related pathways before new prescriptions.</li>
        <li>Discuss <strong>Nabiximols (THC/CBD oromucosal spray)</strong> as preferred therapeutic route given intolerance to sodium-channel and serotonergic agents.</li>
        <li>Provide guidance on safe discontinuation and washout period following last dose.</li>
      </ul>
    </section>

    <section class="section card-like">
      <h2>Patient Statement</h2>
      <p>I have been reluctant with duloxetine, pregabalin, gabapentin, and amitriptyline due to prior experiences. Carbamazepine has produced similar adverse patterns without pain relief. I wish to stop it now and focus on a treatment pathway that does not trigger autonomic or mast-cell reactions. I request support in accessing Nabiximols through NHS pathways or exceptional-case review.</p>
    </section>
  </main>
</body>
</html>
